[1]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
|
[2]YU YC, MAO YM, CHEN CW, et al.CSH guideline for the diagnosis and treatment of drug-induced liver injury[J].Hepatol Int, 2017, 11 (3) :221-241.
|
[3]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.
|
[4]ROCKEY DC, SEEFF LB, ROCHON J, et al.US drug-induced liver injury network.Causality assessment in drug-induced liver injury using a structured expert opinion process:Comparison to the Roussel-Uclaf causality assessment method[J].Hepatology, 2010, 51 (6) :2117-2126.
|
[5]DANAN G, TESCHKE R.Drug-induced liver injury:Why is the roussel uclaf causality assessment method (RUCAM) still used 25years after its launch?[J].Drug Saf, 2018.[Epub ahead of print].
|
[6]DANAN G, BNICHOU C.Causality assessment of adverse reactions to drugs—I.A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46 (11) :1323-1330.
|
[7]DANAN G, TESCHKE R.RUCAM in drug and herb induced liver injury:The update[J].Int J Mol Sci, 2015, 17 (1) .pii:E14.
|
[8]YU YC, CHEN CW.A new version of the Roussel Uclaf Causality Assessment Method:An important assessment tool for drug and herb-induced liver injury[J].Chin Hepatol, 2016, 21 (6) :493-500. (in Chinese) 于乐成, 陈成伟.新版RUCAM:药物和草药诱导性肝损伤的重要评估工具[J].肝脏, 2016, 21 (6) :493-500.
|
[9]YU YC, MAO YM, CHEN CW.A new version of the Roussel Uclaf Causality Assessment Method scale:evaluation and several opinions[J].Chin Hepatol, 2016, 21 (6) :432-433. (in Chinese) 于乐成, 茅益民, 陈成伟.对新版RUCAM量表的评价和几点商榷意见[J].肝脏, 2016, 21 (6) :432-433.
|
[10]HOU JX, PU F, YU YC.Drug rechallenge test for drug-induced liver injury[J].Chin Hepatol, 2017, 22 (11) :978-982. (in Chinese) 侯俊兴, 卜凡, 于乐成.药物性肝损伤的药物再刺激试验[J].肝脏, 2017, 22 (11) :978-982.
|
[11]YU YC, FAN Y, CHEN CW.Rechallenge test for drug-induced liver injury:issues on intentional rechallenge, operation, and judgment[J].Chin Hepatol, 2017, 22 (12) :1073-1076. (in Chinese) 于乐成, 范晔, 陈成伟.药物性肝损伤再刺激试验:能否故意?如何操作?如何判断[J].肝脏, 2017, 22 (12) :1073-1076.
|
[12]YU YC, HE CL, HOU JL.Biomarkers in drug-induced liver injuries[J].J Pract Hepatol, 2014, 17 (6) :564-568. (in Chinese) 于乐成, 何长伦, 侯金林.药物诱导性肝损伤生物标志物研究进展[J].实用肝脏病杂志, 2014, 17 (6) :564-568.
|
[13]WATANABE M, SHIBUYA A.Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales[J].Hepatol Res, 2004, 30 (3) :148-154.
|
[14]WHRITENOUR J, KO M, ZONG Q, et al.Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response[J].J Immunotoxicol, 2017, 14 (1) :31-38.
|
[15]BENESIC A, LEITL A, GERBES AL.Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury[J].Gut, 2016, 65 (9) :1555-1563.
|
[16]CHEN M, BORLAK J, TONG W.A model to predict severity of drug-induced liver injury in humans[J].Hepatology, 2016, 64 (3) :931-940.
|
[17]PROCTOR WR, FOSTER AJ, VOGT J, et al.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury[J].Arch Toxicol, 2017, 91 (8) :2849-2863.
|
[18]VORRINK S, ZHOU Y, INGELMAN-SUNDBERG M, et al.Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions[J].Toxicol Sci, 2018.[Epub ahead of print].
|
[19]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1637.
|
[20]FORD R, SCHWARTZ L, DANCEY J, et al.US Food and Drug Administration.Center for Drug Evaluation and Research (CDER) , Center for Biologics Evaluation and Research (CBER) .Guidance for industry:Drug-induced liver injury—premarketing clinical evaluation[J].Eur J Cancer, 2009, 45 (2) :268-274.
|
[21] Liver Failure and Artificial Liver Group, Chinese Severe Liver Diseases and Artificial Liver Group.Diagnostic and treatment guidelines for liver failure (2012 version) [J].Chin J Hepatol, 2013, 21 (3) :177-183. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝痛与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华肝脏病杂志, 2013, 21 (3) :177-183.
|